Galzus, Looks like you omitted many governance issues like the CEO, CFO, Chairman and her team still have not renewed their employment agreements even while the CEO CFO uses her second private CDMO to run operation at Sawston. You failed to even mention Sawston as a company asset or was that intentional? And, what about revenues from the Specials program, where has it gone?
>>I will say that, despite the lack of comments on the article, it has reached an unusually high traffic amount relative to other biotech articles. If any of you guys were to actually come in and correct what you find is wrong, or report the article for inaccuracies, these would go a long way toward setting the record straight, or forcing me to, assuming the editorial team deems those criticisms valid.t renewed agreements in place
Market Data 
Markets 
AI
